Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) Director Carey Ng acquired 10,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were bought at an average cost of $2.58 per share, for a total transaction of $25,800.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $25,800. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Immix Biopharma Trading Up 5.1 %
Shares of IMMX stock opened at $2.67 on Friday. The firm has a fifty day moving average price of $2.14 and a 200 day moving average price of $2.10. The company has a market cap of $43.49 million, a P/E ratio of -3.34 and a beta of 0.14. Immix Biopharma, Inc. has a 12 month low of $0.68 and a 12 month high of $3.29.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last issued its earnings results on Friday, August 11th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). On average, equities analysts forecast that Immix Biopharma, Inc. will post -0.87 EPS for the current year.
Hedge Funds Weigh In On Immix Biopharma
Analyst Ratings Changes
Separately, Roth Mkm reiterated a “buy” rating and set a $14.00 target price on shares of Immix Biopharma in a research note on Monday, August 14th.
About Immix Biopharma
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
- Five stocks we like better than Immix Biopharma
- What is a Low P/E Ratio and What Does it Tell Investors?
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- Conference Calls and Individual Investors
- MarketBeat Week in Review – 9/11 – 9/15
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.